News
Current Treatment Options for Multiple Myeloma
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. Thanks to advancements in diagnostic methods, it is now understood as a collection of several cytologically distinct plasma cell malignancies. Alongside progress in diagnostics, there has also been rapid development in therapy, significantly improving survival rates for this previously very unfavorable diagnosis, especially in the last 15 years.
In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a…
Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were…
Efficacy and Safety of the Combination of Telmisartan and Amlodipine with Hydrochlorothiazide in the Treatment of Hypertension
The aim of the study by Korean authors was to evaluate the efficacy and tolerability of the triple…
Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients
The quality of life in patients with heart failure is significantly reduced. The concurrent…
CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and...
Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple pharmacokinetic…
Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?
Diabetic autonomic neuropathy can affect various organ systems. Cardiovascular autonomic neuropathy…
Memantine in Dementia Therapy – Current Findings and Possible Future Applications
Memantine is an inhibitor of NMDA receptors, which are pathologically activated by excessive…
Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years old…